|
Post by kc on Jan 17, 2018 13:26:26 GMT -5
GlaxoSmithKline Rumored to be Mulling $1.65B Bid for Partner Vectura Jan 16, 2018
There are rumors that GlaxoSmithKline might make a $1.65 billion bid for UK-based Vectura. That seems like a very specific bit of speculation.
The Telegraph first reported the rumors, citing a possible bid of more than 175 per share, which would be a total bid of around 1.2 billion pounds, or $1.65 billion U.S.
Vectura focuses on devices and formulations for inhaled respiratory medications. Andrew McConaghie, writing for PharmaPhorum, notes, “The biotech firm’s share price fell nearly 40 percent over the course of 2017, largely because the FDA had rejected Vectura and Hikma’s generic version of Advair, but the companies now hope to resolve these problems in Q1 this year.”
GSK is partnered with Vectura already. GSK uses Vectura’s smart inhaler technology in its next-generation Ellipta respiratory products. But McConaghie points out that, although buying Vectura would bolster its respiratory franchise, Vectura has a lot of partnerships with GKS’s competitors. Vectura’s collaborations include Mundipharma, Bayer, and Novartis. They have also all been cited as potential buyers of Vectura.
McConaghie writes, “Its financial problems led Vectura’s chief executive James Ward-Lilley to announce a new business strategy in early January. He unveiled a shift in its focus towards lower risk development opportunities in high potential generics molecules in its pipeline. It will also end new investment in higher risk, novel molecules in early stage programs, and says it will look at opportunities to partner existing programs.”
And if there is an actual bid being planned, that would be a change for GSK as well. Under previous chief executive officer Sir Andrew Witty, the company conducted very little M&A activity. But the new chief executive officer Emma Walmsley is likely taking a different approach.
---
I post this as a reminder that there are big markets for inhalable generics. - MnHoldem Makes one wonder why Amphastar does not make some move for Techno or an interest in MannKind?
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that is engaged in the development, manufacture and marketing of generic and proprietary injectable and inhalation products.
|
|
|
Post by kc on Jan 17, 2018 13:21:57 GMT -5
Since the 10M share placement didn’t occur until Oct, maybe we will see new holders on the next report. According to MNKD website the new(er) numbers are out...Al Mann (foundation, etc.) reduced quite a bit. Also, don't see Deerfield on the list. investors.mannkindcorp.com/ownership-profile.cfm | Shares Held | % O/S | Shares Change | Filing Date | Mann (Alfred E) | 8,806,500 | 7.67 | -13,283,644 | 10/30/2017 | The Vanguard Group, Inc. | 3,154,433 | 2.75 | 614,875 | 09/30/2017 | BlackRock Institutional Trust Company, N.A. | 1,903,040 | 1.66 | 938,387 | 09/30/2017 | Fidelity Management & Research Company | 1,801,400 | 1.57 | 1,801,400 | 11/30/2017 | D. E. Shaw & Co., L.P. | 1,227,979 | 1.07 | 1,188,996 | 09/30/2017 | Scopia Capital Management LP | 982,930 | 0.86 | 0 | 09/30/2017 | Millennium Management LLC | 674,043 | 0.59 | -148,149 | 09/30/2017 | Morgan Stanley & Co. LLC | 645,279 | 0.56 | -285,319 | 09/30/2017 | Balyasny Asset Management LP | 619,800 | 0.54 | 216,800 | 09/30/2017 | Hudson Bay Capital Management LP | 555,779 | 0.48 | 555,779 | 09/30/2017 | Susquehanna Financial Group, LLLP | 552,870 | 0.48 | 312,577 | 09/30/2017 | Goldman Sachs International | 550,744 | 0.48 | 430,744 | 09/30/2017 | Pfeffer (Matthew J) | 538,088 | 0.47 | 442,136 | 10/30/2017 | Geode Capital Management, L.L.C. | 481,026 | 0.42 | 105,954 | 09/30/2017 | Thomson (David) | 384,913 | 0.34 | 312,384 | 10/30/2017 | J.P. Morgan Securities LLC | 302,200 | 0.26 | -251,838 | 09/30/2017 | Norges Bank Investment Management (NBIM) | 272,158 | 0.24 | 25,643 | 12/31/2016 | Kresa (Kent) | 242,605 | 0.21 | 228,572 | 10/30/2017 | Creative Planning, Inc. | 211,823 | 0.18 | 191,318 | 09/30/2017 | Northern Trust Investments, Inc. | 178,147 | 0.16 | -39,140 | 09/30/2017 | Element Capital Management, LLC | 161,841 | 0.14 | -100,099 | 09/30/2017 | Goldman Sachs & Company, Inc. | 153,847 | 0.13 | -1,810,029 | 09/30/2017 | BMO Capital Markets (US) | 150,000 | 0.13 | 150,000 | 09/30/2017 | Dimensional Fund Advisors, L.P. | 124,538 | 0.11 | 124,538 | 09/30/2017 | Charles Schwab Investment Management, Inc. | 117,416 | 0.10 | 11,019 | 09/30/2017 | Bruce & Company, Inc. | 114,927 | 0.10 | 114,927 | 10/31/2017 | State Street Global Advisors (US) | 107,464 | 0.09 | 67,128 | 09/30/2017 | Raymond James & Associates, Inc. | 101,288 | 0.09 | 14,106 | 09/30/2017 | DuPont Capital Management Corporation | 101,000 | 0.09 | 101,000 | 09/30/2017 | Virtu Americas LLC | 91,217 | 0.08 | 6,874 | 09/30/2017 | California Public Employees' Retirement System | 87,060 | 0.08 | 0 | 09/30/2017 | Fortis Advisors, LLC | 79,545 | 0.07 | 79,545 | 09/30/2017 | Macquarie Funds Management Hong Kong Ltd. | 71,780 | 0.06 | 71,780 | 09/30/2017 | Jane Street Capital, L.L.C. | 70,097 | 0.06 | -88,449 | 09/30/2017 | MacCallum (David H) | 70,019 | 0.06 | 57,860 | 10/30/2017 | Friedman (Michael A) | 69,342 | 0.06 | 57,796 | 10/30/2017 | Consiglio (Ronald Joseph) | 68,825 | 0.06 | 56,786 | 10/30/2017 | Nordhoff (Henry L) | 66,249 | 0.06 | 54,844 | 10/30/2017 | Wolverine Trading, LLC | 63,579 | 0.06 | 63,579 | 09/30/2017 | Wells Fargo Advisors | 63,388 | 0.06 | 4,026 | 09/30/2017 | Castagna (Michael E.) | 61,593 | 0.05 | 53,001 | 12/20/2017 | BNY Mellon Asset Management | 60,773 | 0.05 | 0 | 09/30/2017 | Tross Stuart A | 59,840 | 0.05 | 39,840 | 12/21/2017 | BlackRock Advisors (UK) Limited | 53,400 | 0.05 | 53,400 | 09/30/2017 | Urbanski (Raymond W) | 43,591 | 0.04 | 37,827 | 10/30/2017 | Bank of America Merrill Lynch (US) | 40,667 | 0.04 | -13,361 | 09/30/2017 | BNY Mellon Wealth Management | 40,000 | 0.03 | 39,800 | 09/30/2017 | Ladenburg Thalmann Asset Management Inc. (LTAM) | 39,723 | 0.03 | 3,057 | 09/30/2017 | Private Advisor Group LLC | 39,203 | 0.03 | -5,730 | 09/30/2017 | Commonwealth Financial Network | 32,779 | 0.03 | -1,760 | 09/30/2017 |
This purchase if a Institutional investor would make this chart in the next quarter filing. 157,000 shares.
|
|
|
Post by kc on Jan 17, 2018 13:15:59 GMT -5
Maybe Kresa made another buy today to even up his $6.00 purchase. but his last purchase on 10/13/2017 was 166,600 shares.
I guess we will have to wait until Close to see if it him.
|
|
|
Post by kc on Jan 17, 2018 12:53:21 GMT -5
Big block trade of 157,000 shares and the needle didn't move ?
Amazing how that happens? can anybody explain it.
|
|
|
Post by kc on Jan 16, 2018 20:14:28 GMT -5
What is the LA Kong’s........ oh Kings....
Glad its not the LA Bong’s....... That is the new fun activity there.
|
|
|
Post by kc on Jan 16, 2018 11:55:28 GMT -5
The 20th largest institutional holder is Goldman Sachs International, with 120,000 shares. (And it drops off rapidly from there.) I think there are several people on this board who hold more than that. At this point, there are clearly more institutionalized investors than institutional.I now need to replace my keyboard as I spilled my coffee on it when I lost control laughing at your true statement.
|
|
|
Post by kc on Jan 14, 2018 15:27:31 GMT -5
Sorry. It contained a similar situation to what we had in October with HC Wainwright.
|
|
|
Post by kc on Jan 14, 2018 12:10:53 GMT -5
Does this look familar to you? HC WAINWRIGHT? I happen to own some shares in CHEK. But this looks like a familiar method that they used back in October for MannKind
|
|
|
Post by kc on Jan 11, 2018 20:13:12 GMT -5
430......This week and 430 next week. Then moving to 525
|
|
|
Post by kc on Jan 9, 2018 17:15:07 GMT -5
I think that Mike solved the Liquidity issue. On October 1, 2017 MannKind invested 15,000,000 in to Bitcoin when it was trading at $4,404.00 per share. for 3,405.09 Bitcoins.
He didn't sell them on December 16th when they hit $19,187 per coin as he was greedy with MannKind's money. ($65,333,461). He figured they would continue to go up in value and we didn't need the cash until the 2nd quarter.
Today's value is $14,699.00 per Bitcoin or $50,051,417 So should Mike sell MannKind's Bitcoin's or wait for the next run up in value. Since one of their lottery tickets hit the jackpot last week, I think we can hold off on liquidating the bitcoin, though couldn't hurt to take some off the table to be prudent... just in case the lamp Mike just bought doesn't actually contain a genie. Goldman Sachs said all the lamps they sell have genies in them.
|
|
|
Post by kc on Jan 9, 2018 16:31:10 GMT -5
I think that Mike solved the Liquidity issue. On October 1, 2017 MannKind invested 15,000,000 in to Bitcoin when it was trading at $4,404.00 per share. for 3,405.09 Bitcoins.
He didn't sell them on December 16th when they hit $19,187 per coin as he was greedy with MannKind's money. ($65,333,461). He figured they would continue to go up in value and we didn't need the cash until the 2nd quarter.
Today's value is $14,699.00 per Bitcoin or $50,051,417 So should Mike sell MannKind's Bitcoin's or wait for the next run up in value.
|
|
|
Post by kc on Jan 9, 2018 12:37:55 GMT -5
No but is focused on a buyer who will purchase a % of the company and not the entire company. I believe they want somebody who will handle the international sales aspect and let MannKind continue to building the US sales market. The Company and its board understands the value of the product and they factory producing Afrezza. They also understand the wishes not that they matter of Al Mann (the Family) to get the value of the investment out of the company. Will that ever happen? Who knows. So far we are all losers as we have hitched our wagons to that theory.
Actually I think that Mike answered the question in a tweet today.
|
|
|
Post by kc on Jan 8, 2018 18:38:52 GMT -5
No need for rumors, I emailed IR and asked when the next Shareholder update would be: me: Hi Rose, In the past there has been share holder update calls or conference events. Will there be anything similar or will the next update be on the quarterly call? Rose: Hi X, We are at the JP Morgan Conference this week in, literally, back to back meetings. We are not presenting so there is no public webcast. Unless Mike and Steve feel there are material outcomes this week which require us to announce publicly, our next planned Investor call is the earnings call.
Now that is throwing up some chum......
Hi X, We are at the JP Morgan Conference this week in, literally, back to back meetings. We are not presenting so there is no public webcast. Unless Mike and Steve feel there are material outcomes this week which require us to announce publicly, our next planned Investor call is the earnings call.
|
|
|
Post by kc on Jan 8, 2018 18:00:47 GMT -5
Just listened to the J & J presentation. That is a company with a lot of Cash. Would MannKind be a good bolt on to their Janssen line?
|
|
|
Post by kc on Jan 8, 2018 16:48:08 GMT -5
The Lunchtime Keynote was interesting.
Keynote: Bill Gates
Grand Ballroom Speaker Bill Gates , Co-chair and Trustee , Bill & Melinda Gates Foundation
Interviewed by Dr. Sanjay Gupta , Chief Medical Correspondent , CNN
Webcast to be available later today.
|
|